WallStSmart

BridgeBio Pharma Inc (BBIO)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BridgeBio Pharma Inc generates 78061% more annual revenue ($579.96M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -124.4%. BBIO earns a higher WallStSmart Score of 31/100 (F).

BBIO

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: -6.99

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BBIOUndervalued (+87.8%)

Margin of Safety

+87.8%

Fair Value

$547.00

Current Price

$67.33

$479.67 discount

UndervaluedFair: $547.00Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BBIO2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
66.8%10/10

Revenue surging 66.8% year-over-year

Debt/EquityHealth
-1.4910/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

BBIO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-1790.0%2/10

ROE of -1790.0% — below average capital efficiency

Free Cash FlowQuality
$-197.35M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BBIO

The strongest argument for BBIO centers on Revenue Growth, Debt/Equity. Revenue growth of 66.8% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : BBIO

The primary concerns for BBIO are EPS Growth, Piotroski F-Score, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

BBIO profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

BBIO is growing revenue faster at 66.8% — sustainability is the question.

BBIO generates stronger free cash flow (-197M), providing more financial flexibility.

Bottom Line

BBIO scores higher overall (31/100 vs 24/100) and 66.8% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BridgeBio Pharma Inc

HEALTHCARE · BIOTECHNOLOGY · USA

BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?